EP Patent

EP0414632B1 — Cyclosporin derivatives

Assigned to Novartis AG · Expires 1996-10-23 · 30y expired

What this patent protects

Hydroxy-substituted [(D)Ser]<8>-Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser]<8>-Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune dise…

USPTO Abstract

Hydroxy-substituted [(D)Ser]<8>-Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser]<8>-Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.

Drugs covered by this patent

Patent Metadata

Patent number: EP0414632B1
Jurisdiction: EP
Classification: —
Expires: 1996-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.